Evidence map›Paper›PMID 42087141›Full record

ArticleJournal of translational medicine2026

A novel combination for in vivo breast cancer treatment: TAK1 inhibition combined with metformin and Lentinula edodes compounds synergistically reinvigorates CD8

Amir Saeid Mahdavi, Nader Bagheri, Francesco M Marincola, Pegah Khosravian, Mahdi Ghatrehsamani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amir Saeid MahdaviClinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Nader BagheriCancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Francesco M MarincolaTranslational and Advanced Medicine (TAM) Biosciences, Nashville, TN, USA.
Pegah KhosravianMedical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Mahdi GhatrehsamaniCellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, PO Box: 88155-571, Shahrekord, Iran. mahdi.samani.2020@gmail.com.

Funding

Shahrekord University of Medical Sciences 4719
6 · The paper itself

Abstract

backgroundBreast cancer (BC) is the most prevalent cancer among women, and retrieving the anti-tumor function of the immune system seems a promising treatment approach for its crucial role in combating cancer cells. In this study, we evaluated the impact of a combination therapy containing a TAK1 inhibitor, Takinib (Tak), a metabolic regulator, Metformin (Met), and an immunostimulant, Lentinula edodes mycelia extract (LEME) on enhancing the immune system's anti-tumor activity in BALB/c mice bearing triple-negative breast cancer (TNBC).

methodsBALB/c mice were used to induce TNBC tumors and evaluate tumor growth inhibition. The number of CD8

resultsMolecular docking results revealed significant interactions between Tak and Met with TOX and NR4A1. The combination treatments of Tak, Met, and LEME significantly decreased tumor volume/weight in mice and also significantly increased the number of infiltrated CD8

conclusionThis study suggests that the Tak-Met-LEME combination treatments may inhibit BC progression by increasing CD8

Indexed as

Breast NeoplasmsCD8-Positive T-LymphocytesMAP Kinase Kinase KinasesMetforminProtein Kinase InhibitorsShiitake MushroomsTriple Negative Breast NeoplasmsAnimalsCell Line, TumorCell ProliferationDrug SynergismFemaleHumansMAP Kinase Kinase Kinase 7MiceMice, Inbred BALB CMAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesMetforminMucin-1Protein Kinase InhibitorsCD8+ CD28+ T cellsCombination therapyLentinula edodesMetforminTakinibTriple-negative breast cancer

Identifiers

PMID42087141
PMCPMC13151377

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.